Efficacy and safety of sintilimab in combination with chemotherapy for recurrent extensive-stage small cell lung cancer: a real-world retrospective study

被引：0

作者：

Wang, Jingyi ^{[1
,2
]}

Liang, Shuzhi ^{[1
]}

Xu, Li ^{[1
]}

Kong, Yi ^{[1
]}

Seki, Nobuhiko ^{[1
,3
]}

Ganti, Apar Kishor ^{[4
,5
]}

Neal, Joel W. ^{[6
]}

Li, Jia ^{[1
]}

Xu, Fang ^{[1
]}

Li, Kang ^{[1
]}

Xu, Yan ^{[1
]}

Wu, Lin ^{[1
]}

Chen, Bolin ^{[1
]}

机构：

[1] Cent South Univ, Hunan Canc Hosp, Dept Thorac Oncol 2, Affiliated Canc Hosp,Xiangya Sch Med, Tongzipo Rd 283, Changsha 410013, Peoples R China

[2] Cent South Univ, Xiangya Hosp, Dept Geriatr Resp Med, Changsha, Peoples R China

[3] Teikyo Univ, Sch Med, Dept Internal Med, Div Med Oncol, Tokyo, Japan

[4] VA Nebraska Western Iowa Hlth Care Syst, Dept Internal Med, Div Oncol Hematol, Omaha, NE USA

[5] Univ Nebraska Med Ctr, Omaha, NE USA

[6] Stanford Canc Inst, Dept Med, Div Oncol, Stanford, CA USA

来源：

JOURNAL OF THORACIC DISEASE | 2024年 / 16卷 / 06期

关键词：

Small cell lung cancer (SCLC); immune checkpoint inhibitors (ICIs); sintilimab; immune-combination therapy; NIVOLUMAB PLUS IPILIMUMAB; OPEN-LABEL; 2ND-LINE TREATMENT; CHECKMATE; 032; MULTICENTER; 1ST-LINE; SCLC; PEMBROLIZUMAB; LURBINECTEDIN; ETOPOSIDE;

D O I：

10.21037/jtd-24-769

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

Background: Immune checkpoint inhibitors (ICIs) no longer are approved for second-line or later treatment of extensive-stage small cell lung cancer (ES-SCLC), and have not been studied in combination with chemotherapy. Exploring the efficacy and safety of second-line or later immunotherapy for ES-SCLC is an urgent clinical question that needs to be addressed, and combination therapies are an important research direction. This study intended to investigate the efficacy and safety of the sintilimab in combination with chemotherapy as a second-line and beyond treatment option for ES-SCLC. Methods: Medical records of patients who received treatment with sintilimab in combination with chemotherapy or chemotherapy alone as a second-line or beyond therapy were retrospectively analyzed. The study evaluated efficacy and safety. Indicators of efficacy included objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS). Safety indicators included adverse events (AEs). Results: This cohort comprised of 46 patients: 24 in the sintilimab combination chemotherapy group and 22 in the chemotherapy group. Chemotherapy received by both groups was either albumin-bound paclitaxel or irinotecan. Compared with the chemotherapy group, the sintilimab combination chemotherapy group had higher ORR and DCR (ORR: 37.5% vs. 9.1%, P=0.04; DCR: 75.0% vs. 40.9%, P=0.04), and significantly prolonged PFS and OS [median PFS (mPFS): 5.07 vs. 2.45 months, P=0.006; median OS (mOS): 14.43 vs. 10.34 months, P=0.009]. Also, there was no significant increase in the incidence of AEs in the sintilimab combination chemotherapy group, which was well tolerated by patients. Conclusions: Sintilimab in combination with chemotherapy is superior to single-agent chemotherapeutic treatment as second-line or later therapy in ES-SCLC patients who have not received prior immunotherapy. These results need to be confirmed in future clinical trials.

引用

页码：3897 / 3908

页数：12

共 37 条

[11] Using the Common Terminology Criteria for Adverse Events (CTCAE - Version 5.0) to Evaluate the Severity of Adverse Events of Anticancer Therapies [J].

Freites-Martinez, A. ;

Santana, N. ;

Arias-Santiago, S. ;

Viera, A. .

ACTAS DERMO-SIFILIOGRAFICAS, 2021, 112 (01) :90-92

[12] Phase II Study of Maintenance Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC) [J].

Gadgeel, Shirish M. ;

Pennell, Nathan A. ;

Fidler, Mary Jo ;

Halmos, Balazs ;

Bonomi, Philip ;

Stevenson, James ;

Schneider, Bryan ;

Sukari, Ammar ;

Ventimiglia, Jaclyn ;

Chen, Wei ;

Galasso, Cathy ;

Wozniak, Antoinette ;

Boerner, Julie ;

Kalemkerian, Gregory P. .

JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (09) :1393-1399

[13] Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial [J].

Goldman, Jonathan W. ;

Dvorkin, Mikhail ;

Chen, Yuanbin ;

Reinmuth, Niels ;

Hotta, Katsuyuki ;

Trukhin, Dmytro ;

Statsenko, Galina ;

Hochmair, Maximilian J. ;

Ozguroglu, Mustafa ;

Ji, Jun Ho ;

Garassino, Marina Chiara ;

Voitko, Oleksandr ;

Poltoratskiy, Artem ;

Ponce, Santiago ;

Verderame, Francesco ;

Havel, Libor ;

Bondarenko, Igor ;

Kazarnowicz, Andrzej ;

Losonczy, Gyorgy ;

Conev, Nikolay V. ;

Armstrong, Jon ;

Byrne, Natalie ;

Thiyagarajah, Piruntha ;

Jiang, Haiyi ;

Paz-Ares, Luis .

LANCET ONCOLOGY, 2021, 22 (01) :51-65

[14] First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer [J].

Horn, L. ;

Mansfield, A. S. ;

Szczesna, A. ;

Havel, L. ;

Krzakowski, M. ;

Hochmair, M. J. ;

Huemer, F. ;

Losonczy, G. ;

Johnson, M. L. ;

Nishio, M. ;

Reck, M. ;

Mok, T. ;

Lam, S. ;

Shames, D. S. ;

Liu, J. ;

Ding, B. ;

Lopez-Chavez, A. ;

Kabbinavar, F. ;

Lin, W. ;

Sandler, A. ;

Liu, S. V. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (23) :2220-2229

[15] Camrelizumab combined with anlotinib for the treatment of small cell lung cancer: a case report and literature review [J].

Jiang, Yuqi ;

Zhang, Lei ;

Zhu, Fuyun ;

Zhu, Hui ;

Cao, Xiaowen ;

Zhang, Yongchun .

ANNALS OF PALLIATIVE MEDICINE, 2022, 11 (03) :1135-1146

[16] A phase II study of pembrolizumab and paclitaxel in patients with relapsed or refractory small-cell lung cancer [J].

Kim, Yu-Jung ;

Keam, Bhumsuk ;

Ock, Chan-Young ;

Song, Sanghoon ;

Kim, Miso ;

Kim, Se Hyun ;

Kim, Ki Hwan ;

Kim, Jin-Soo ;

Kim, Tae Min ;

Kim, Dong-Wan ;

Lee, Jong Seok ;

Heo, Dae Seog .

LUNG CANCER, 2019, 136 :122-128

[17] Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133) [J].

Liu, Stephen, V ;

Reck, Martin ;

Mansfield, Aaron S. ;

Mok, Tony ;

Scherpereel, Arnaud ;

Reinmuth, Niels ;

Garassino, Marina Chiara ;

Carpeno, Javier De Castro ;

Califano, Raffaele ;

Nishio, Makoto ;

Orlandi, Francisco ;

Alatorre-Alexander, Jorge ;

Leal, Ticiana ;

Cheng, Ying ;

Lee, Jong-Seok ;

Lam, Sivuonthanh ;

McCleland, Mark ;

Deng, Yu ;

Phan, See ;

Horn, Leora .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06) :619-+

[18] Sintilimab plus anlotinib as second or further-line therapy for extensive disease small cell lung cancer: a phase 2 investigator-initiated non-randomized controlled trial [J].

Ma, Shuxiang ;

He, Zhen ;

Liu, Yang ;

Wang, Lili ;

Yang, Sen ;

Wu, Yufeng ;

Chen, Haiyang ;

Wu, Yingxi ;

Wang, Qiming .

ECLINICALMEDICINE, 2024, 70

[19]

Ma SX, 2022, J CLIN ONCOL, V40

[20] Lurbinectedin in small cell lung cancer [J].

Manzo, Anna ;

Sforza, Vincenzo ;

Carillio, Guido ;

Palumbo, Giuliano ;

Montanino, Agnese ;

Sandomenico, Claudia ;

Costanzo, Raffaele ;

Esposito, Giovanna ;

Laudato, Francesca ;

Mercadante, Edoardo ;

La Manna, Carmine ;

Muto, Paolo ;

Totaro, Giuseppe ;

De Cecio, Rossella ;

Picone, Carmine ;

Piccirillo, Maria Carmela ;

Pascarella, Giacomo ;

Normanno, Nicola ;

Morabito, Alessandro .

FRONTIERS IN ONCOLOGY, 2022, 12

← 1 2 3 4 →